COMP360 psilocybin treatment in TRD (Treatment Resistant Depression) • Positive primary endpoint achieved in first COMP360 Phase 3 trial with high statistical significance, clinically meaningful reduction in depression at 6 weeks, and no unexpected safety findings • Second ongoing pivotal Phase 3 trial continues to enroll well, with 26-week data expected in the second half of 2026 • Compass exploring options for potential accelerated COMP360 filing for TRD • Cash position of $221.9 million at June 30, 2025; ...